| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytosis, Langerhans-Cell | 50 | 2024 | 212 | 13.450 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 27 | 2024 | 144 | 6.690 |
Why?
|
| Proto-Oncogene Proteins B-raf | 18 | 2024 | 160 | 3.020 |
Why?
|
| Langerhans Cells | 7 | 2021 | 21 | 2.410 |
Why?
|
| Xanthogranuloma, Juvenile | 7 | 2022 | 30 | 1.960 |
Why?
|
| Dendritic Cells | 13 | 2023 | 401 | 1.740 |
Why?
|
| Histiocytosis, Sinus | 6 | 2022 | 29 | 1.460 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2024 | 519 | 1.260 |
Why?
|
| Ferritins | 6 | 2021 | 95 | 1.140 |
Why?
|
| Child | 67 | 2024 | 23789 | 1.100 |
Why?
|
| Cell Differentiation | 9 | 2023 | 1933 | 1.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2023 | 1189 | 1.070 |
Why?
|
| Erdheim-Chester Disease | 5 | 2023 | 22 | 1.060 |
Why?
|
| Macrophage Activation Syndrome | 3 | 2023 | 11 | 1.050 |
Why?
|
| MAP Kinase Signaling System | 8 | 2024 | 319 | 1.020 |
Why?
|
| Humans | 134 | 2024 | 121793 | 1.010 |
Why?
|
| Mannose-Binding Lectins | 8 | 2020 | 23 | 1.000 |
Why?
|
| Transplantation Conditioning | 5 | 2020 | 322 | 0.990 |
Why?
|
| Mutation | 19 | 2023 | 5773 | 0.990 |
Why?
|
| Lectins, C-Type | 8 | 2020 | 68 | 0.980 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2024 | 284 | 0.930 |
Why?
|
| Neurodegenerative Diseases | 3 | 2018 | 250 | 0.890 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 116 | 0.890 |
Why?
|
| T-Lymphocytes | 7 | 2024 | 1677 | 0.870 |
Why?
|
| Child, Preschool | 39 | 2024 | 13661 | 0.870 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 87 | 0.840 |
Why?
|
| Herpesvirus 4, Human | 5 | 2024 | 662 | 0.840 |
Why?
|
| Myeloid Cells | 4 | 2023 | 97 | 0.830 |
Why?
|
| DNA-Binding Proteins | 11 | 2011 | 2032 | 0.830 |
Why?
|
| Antigens, CD | 7 | 2020 | 421 | 0.830 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1242 | 0.830 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 168 | 0.820 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 326 | 0.810 |
Why?
|
| Adolescent | 40 | 2024 | 18773 | 0.770 |
Why?
|
| Infant | 31 | 2024 | 12177 | 0.770 |
Why?
|
| Precision Medicine | 3 | 2022 | 306 | 0.760 |
Why?
|
| Sepsis | 4 | 2021 | 477 | 0.760 |
Why?
|
| Hodgkin Disease | 6 | 2023 | 289 | 0.750 |
Why?
|
| Zinc Fingers | 7 | 2011 | 114 | 0.730 |
Why?
|
| Lymphoma | 3 | 2023 | 318 | 0.730 |
Why?
|
| Sarcoma, Kaposi | 4 | 2023 | 108 | 0.730 |
Why?
|
| Histiocytosis | 5 | 2020 | 19 | 0.720 |
Why?
|
| Disease Susceptibility | 2 | 2022 | 297 | 0.720 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 329 | 0.700 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 353 | 0.700 |
Why?
|
| Cell Movement | 2 | 2021 | 838 | 0.700 |
Why?
|
| Interleukin-17 | 2 | 2011 | 118 | 0.670 |
Why?
|
| Neoplasms | 6 | 2023 | 2697 | 0.600 |
Why?
|
| Osteopontin | 1 | 2018 | 49 | 0.600 |
Why?
|
| Male | 56 | 2024 | 59243 | 0.600 |
Why?
|
| Interleukin-18 | 1 | 2018 | 60 | 0.590 |
Why?
|
| Smad6 Protein | 1 | 2017 | 6 | 0.590 |
Why?
|
| Female | 55 | 2024 | 64573 | 0.550 |
Why?
|
| Leukemia | 1 | 2020 | 357 | 0.550 |
Why?
|
| Skin Diseases | 2 | 2015 | 121 | 0.540 |
Why?
|
| Cytokines | 7 | 2021 | 1284 | 0.530 |
Why?
|
| NF-kappa B | 5 | 2007 | 462 | 0.530 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2024 | 223 | 0.520 |
Why?
|
| Lymphocytes | 2 | 2015 | 402 | 0.520 |
Why?
|
| Histiocytes | 3 | 2022 | 23 | 0.510 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 303 | 0.510 |
Why?
|
| Adult | 32 | 2024 | 28549 | 0.500 |
Why?
|
| Young Adult | 16 | 2024 | 8676 | 0.490 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2022 | 207 | 0.480 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 194 | 0.480 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2014 | 10 | 0.480 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2014 | 10 | 0.480 |
Why?
|
| Cell Degranulation | 1 | 2014 | 29 | 0.470 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2023 | 158 | 0.470 |
Why?
|
| Cytarabine | 2 | 2015 | 99 | 0.460 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 83 | 0.460 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 400 | 0.450 |
Why?
|
| Hematologic Neoplasms | 4 | 2018 | 268 | 0.450 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 2997 | 0.450 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1672 | 0.450 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 1587 | 0.430 |
Why?
|
| Antigens, CD1 | 4 | 2020 | 21 | 0.430 |
Why?
|
| Interferon-gamma | 3 | 2022 | 511 | 0.410 |
Why?
|
| Alemtuzumab | 5 | 2023 | 88 | 0.410 |
Why?
|
| Central Nervous System Diseases | 2 | 2010 | 104 | 0.400 |
Why?
|
| Transcription Factors | 8 | 2020 | 2580 | 0.400 |
Why?
|
| Diagnosis, Differential | 6 | 2021 | 1868 | 0.400 |
Why?
|
| Models, Genetic | 2 | 2014 | 740 | 0.390 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2024 | 501 | 0.390 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 45 | 0.390 |
Why?
|
| Biomarkers | 7 | 2021 | 2926 | 0.380 |
Why?
|
| Autoimmune Diseases | 3 | 2020 | 248 | 0.380 |
Why?
|
| Models, Biological | 4 | 2014 | 1437 | 0.370 |
Why?
|
| Vincristine | 2 | 2020 | 206 | 0.370 |
Why?
|
| Disease-Free Survival | 4 | 2024 | 860 | 0.360 |
Why?
|
| Transforming Growth Factor beta | 3 | 2017 | 460 | 0.360 |
Why?
|
| Perforin | 3 | 2021 | 18 | 0.360 |
Why?
|
| Enzyme Activation | 3 | 2016 | 620 | 0.350 |
Why?
|
| Biopsy | 4 | 2021 | 1253 | 0.350 |
Why?
|
| Epidermis | 1 | 2010 | 61 | 0.340 |
Why?
|
| Lymphoma, T-Cell | 2 | 2021 | 65 | 0.340 |
Why?
|
| Hydrocephalus | 2 | 2010 | 236 | 0.330 |
Why?
|
| Treatment Outcome | 12 | 2024 | 12003 | 0.330 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 1165 | 0.320 |
Why?
|
| Granulomatous Disease, Chronic | 2 | 2020 | 65 | 0.320 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 73 | 0.310 |
Why?
|
| Monocytes | 3 | 2023 | 343 | 0.310 |
Why?
|
| Genes, ras | 1 | 2008 | 96 | 0.310 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 284 | 0.310 |
Why?
|
| Bone Marrow | 5 | 2021 | 315 | 0.310 |
Why?
|
| Retrospective Studies | 18 | 2024 | 15794 | 0.300 |
Why?
|
| Glioma | 2 | 2022 | 467 | 0.300 |
Why?
|
| Adenine Nucleotides | 3 | 2024 | 41 | 0.290 |
Why?
|
| Arabinonucleosides | 3 | 2024 | 32 | 0.290 |
Why?
|
| HIV Infections | 4 | 2023 | 1842 | 0.290 |
Why?
|
| Animals | 23 | 2021 | 33870 | 0.290 |
Why?
|
| Prednisone | 4 | 2016 | 272 | 0.290 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2020 | 38 | 0.280 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1675 | 0.280 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1078 | 0.280 |
Why?
|
| HLA-DR Antigens | 2 | 2021 | 76 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 629 | 0.280 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 195 | 0.280 |
Why?
|
| Vinblastine | 3 | 2016 | 45 | 0.280 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 169 | 0.280 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2021 | 538 | 0.270 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 107 | 0.270 |
Why?
|
| Pyrazoles | 2 | 2020 | 301 | 0.260 |
Why?
|
| Burkitt Lymphoma | 2 | 2020 | 146 | 0.260 |
Why?
|
| Prognosis | 7 | 2024 | 4438 | 0.260 |
Why?
|
| Disease Progression | 5 | 2018 | 1984 | 0.260 |
Why?
|
| Genome | 1 | 2008 | 471 | 0.260 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 323 | 0.260 |
Why?
|
| Positron-Emission Tomography | 3 | 2013 | 283 | 0.260 |
Why?
|
| Disease Management | 5 | 2021 | 511 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 1021 | 0.250 |
Why?
|
| B-Lymphocytes | 2 | 2013 | 518 | 0.250 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2829 | 0.240 |
Why?
|
| Recombination, Genetic | 3 | 2002 | 446 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2023 | 3132 | 0.240 |
Why?
|
| Salvage Therapy | 3 | 2024 | 192 | 0.240 |
Why?
|
| Apoptosis | 4 | 2021 | 1791 | 0.240 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2002 | 297 | 0.230 |
Why?
|
| Immune System Diseases | 2 | 2017 | 45 | 0.230 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 21 | 0.230 |
Why?
|
| Bortezomib | 1 | 2024 | 74 | 0.230 |
Why?
|
| Lung Diseases | 2 | 2020 | 383 | 0.230 |
Why?
|
| Mice | 18 | 2021 | 17624 | 0.220 |
Why?
|
| DNA | 4 | 2007 | 1606 | 0.220 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 208 | 0.220 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 774 | 0.220 |
Why?
|
| Spleen | 1 | 2024 | 287 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 136 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 46 | 0.210 |
Why?
|
| Survival Analysis | 2 | 2018 | 1463 | 0.210 |
Why?
|
| Melphalan | 2 | 2023 | 49 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 15 | 0.210 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 12 | 0.210 |
Why?
|
| Infant, Newborn | 6 | 2020 | 8009 | 0.210 |
Why?
|
| Thoracic Neoplasms | 1 | 2002 | 34 | 0.210 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 266 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1103 | 0.210 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 49 | 0.210 |
Why?
|
| Protein Sorting Signals | 1 | 2002 | 38 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 3441 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 83 | 0.200 |
Why?
|
| Lymph Nodes | 3 | 2020 | 377 | 0.200 |
Why?
|
| Rheumatology | 1 | 2023 | 105 | 0.200 |
Why?
|
| Wilms Tumor | 1 | 2023 | 112 | 0.190 |
Why?
|
| Pneumococcal Infections | 1 | 2024 | 274 | 0.190 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2001 | 28 | 0.190 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 88 | 0.190 |
Why?
|
| Transcription, Genetic | 5 | 2003 | 1703 | 0.190 |
Why?
|
| Teratoma | 1 | 2002 | 125 | 0.190 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 679 | 0.190 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 17 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 864 | 0.190 |
Why?
|
| Benzimidazoles | 1 | 2022 | 128 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 999 | 0.190 |
Why?
|
| Growth Disorders | 1 | 2002 | 208 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 1881 | 0.180 |
Why?
|
| Cell Lineage | 3 | 2023 | 347 | 0.180 |
Why?
|
| CD3 Complex | 2 | 2011 | 84 | 0.180 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 62 | 0.180 |
Why?
|
| Signal Transduction | 6 | 2020 | 4518 | 0.180 |
Why?
|
| Malawi | 4 | 2023 | 383 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 813 | 0.180 |
Why?
|
| Remission Induction | 3 | 2017 | 300 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 4385 | 0.180 |
Why?
|
| Glycoproteins | 2 | 2020 | 371 | 0.170 |
Why?
|
| Thiotepa | 1 | 2020 | 15 | 0.170 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 23 | 0.170 |
Why?
|
| Medical Oncology | 2 | 2023 | 208 | 0.170 |
Why?
|
| Gastroenteritis | 1 | 2023 | 333 | 0.170 |
Why?
|
| Mitosis | 1 | 2000 | 239 | 0.170 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 390 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 2021 | 158 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 231 | 0.170 |
Why?
|
| Genome, Human | 2 | 2018 | 1255 | 0.170 |
Why?
|
| ROC Curve | 2 | 2014 | 544 | 0.170 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 21 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 97 | 0.160 |
Why?
|
| Pneumothorax | 1 | 2020 | 81 | 0.160 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 198 | 0.160 |
Why?
|
| Brain | 4 | 2023 | 2941 | 0.160 |
Why?
|
| Dexamethasone | 1 | 2020 | 274 | 0.160 |
Why?
|
| Anemia | 1 | 2023 | 337 | 0.160 |
Why?
|
| Genotype | 2 | 2015 | 2483 | 0.160 |
Why?
|
| Mutation, Missense | 2 | 2021 | 840 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 414 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 424 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2021 | 428 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 203 | 0.160 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 35 | 0.160 |
Why?
|
| Hematology | 1 | 2018 | 35 | 0.150 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 66 | 0.150 |
Why?
|
| Vidarabine | 1 | 2018 | 79 | 0.150 |
Why?
|
| Down-Regulation | 1 | 2000 | 701 | 0.150 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 13 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 472 | 0.150 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 22 | 0.150 |
Why?
|
| Genetic Testing | 3 | 2021 | 988 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 42 | 0.150 |
Why?
|
| Bone Marrow Cells | 2 | 2017 | 261 | 0.150 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 19 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 2031 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 37 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 48 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 53 | 0.140 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 60 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 72 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 111 | 0.140 |
Why?
|
| Recurrence | 4 | 2024 | 1408 | 0.140 |
Why?
|
| Physicians | 1 | 2023 | 582 | 0.140 |
Why?
|
| Africa South of the Sahara | 3 | 2023 | 112 | 0.140 |
Why?
|
| Abnormalities, Multiple | 1 | 2002 | 967 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 133 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 138 | 0.140 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2016 | 2 | 0.130 |
Why?
|
| Thiophenes | 1 | 2016 | 60 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 4953 | 0.130 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2016 | 15 | 0.130 |
Why?
|
| Liver Diseases | 2 | 2018 | 383 | 0.130 |
Why?
|
| Hydroxyurea | 1 | 2016 | 78 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2017 | 223 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1149 | 0.130 |
Why?
|
| Protein Domains | 1 | 2016 | 233 | 0.130 |
Why?
|
| Radiation Dosage | 2 | 2013 | 131 | 0.120 |
Why?
|
| Ataxia Telangiectasia | 1 | 1994 | 16 | 0.120 |
Why?
|
| Vaginal Diseases | 1 | 2015 | 17 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2014 | 19 | 0.120 |
Why?
|
| Epithelial Cells | 2 | 2010 | 907 | 0.120 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 54 | 0.120 |
Why?
|
| Critical Illness | 2 | 2021 | 589 | 0.120 |
Why?
|
| United States | 8 | 2024 | 10413 | 0.120 |
Why?
|
| Antigens | 1 | 2015 | 156 | 0.120 |
Why?
|
| Pediatrics | 2 | 2018 | 1137 | 0.120 |
Why?
|
| Inflammation | 3 | 2021 | 1393 | 0.120 |
Why?
|
| Algorithms | 1 | 2021 | 1569 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 201 | 0.120 |
Why?
|
| Family | 1 | 2017 | 561 | 0.120 |
Why?
|
| Immune System | 1 | 2015 | 86 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1032 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 1590 | 0.120 |
Why?
|
| Consensus | 3 | 2023 | 604 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2074 | 0.110 |
Why?
|
| Immunotherapy | 3 | 2018 | 655 | 0.110 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 60 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 542 | 0.110 |
Why?
|
| Genes, p53 | 1 | 1994 | 215 | 0.110 |
Why?
|
| Cell Division | 2 | 2009 | 793 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 338 | 0.110 |
Why?
|
| Immunoprecipitation | 2 | 2011 | 198 | 0.110 |
Why?
|
| DNA Damage | 1 | 2017 | 517 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 142 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 492 | 0.110 |
Why?
|
| Phenotype | 4 | 2019 | 4200 | 0.110 |
Why?
|
| GATA2 Transcription Factor | 1 | 2013 | 45 | 0.110 |
Why?
|
| Aged | 8 | 2024 | 18732 | 0.110 |
Why?
|
| Research Design | 1 | 2017 | 645 | 0.110 |
Why?
|
| Castleman Disease | 1 | 2013 | 13 | 0.110 |
Why?
|
| Mediastinal Diseases | 1 | 2013 | 14 | 0.110 |
Why?
|
| Texas | 3 | 2018 | 3431 | 0.110 |
Why?
|
| Mediastinum | 1 | 2013 | 41 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 342 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 137 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 167 | 0.100 |
Why?
|
| Base Sequence | 5 | 2017 | 3117 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 44 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 136 | 0.100 |
Why?
|
| Macrophages | 1 | 2016 | 612 | 0.100 |
Why?
|
| Registries | 1 | 2018 | 1318 | 0.100 |
Why?
|
| Middle Aged | 8 | 2024 | 25516 | 0.090 |
Why?
|
| Parents | 1 | 2018 | 1006 | 0.090 |
Why?
|
| Osteoclasts | 1 | 2011 | 52 | 0.090 |
Why?
|
| Risk Factors | 6 | 2023 | 9718 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2017 | 3777 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2020 | 2 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2020 | 8 | 0.090 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2020 | 11 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 5960 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1300 | 0.090 |
Why?
|
| Osteogenesis | 1 | 2011 | 154 | 0.090 |
Why?
|
| Exome | 1 | 2015 | 1034 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 167 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2023 | 420 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 1401 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1414 | 0.080 |
Why?
|
| Blotting, Southern | 2 | 2007 | 217 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2020 | 255 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 4623 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2511 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 1105 | 0.080 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2008 | 19 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2011 | 2539 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1759 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2009 | 146 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2009 | 228 | 0.080 |
Why?
|
| Databases, Genetic | 2 | 2019 | 467 | 0.080 |
Why?
|
| Survival Rate | 3 | 2017 | 1976 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3075 | 0.070 |
Why?
|
| Cell Line | 4 | 2011 | 2787 | 0.070 |
Why?
|
| Accident Prevention | 1 | 1987 | 9 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 2962 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1520 | 0.070 |
Why?
|
| Protein Binding | 4 | 2011 | 1736 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 48 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2321 | 0.070 |
Why?
|
| Genomics | 3 | 2022 | 1467 | 0.070 |
Why?
|
| Bicycling | 1 | 1987 | 39 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 817 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2009 | 262 | 0.070 |
Why?
|
| Physician Executives | 1 | 2006 | 40 | 0.070 |
Why?
|
| Athletic Injuries | 1 | 1987 | 54 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 1987 | 99 | 0.070 |
Why?
|
| Sports | 1 | 1987 | 59 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 414 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 569 | 0.070 |
Why?
|
| Transfection | 2 | 2000 | 1076 | 0.060 |
Why?
|
| Fatigue | 2 | 2023 | 208 | 0.060 |
Why?
|
| DNA Primers | 1 | 2007 | 668 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 2438 | 0.060 |
Why?
|
| Workload | 1 | 2006 | 145 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1244 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 1206 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3289 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4306 | 0.060 |
Why?
|
| Binding Sites | 3 | 2003 | 1294 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 744 | 0.060 |
Why?
|
| Rheumatic Diseases | 1 | 2024 | 66 | 0.060 |
Why?
|
| Gene Expression | 2 | 2017 | 1589 | 0.060 |
Why?
|
| Rats | 2 | 2008 | 3659 | 0.060 |
Why?
|
| Chemokine CXCL9 | 1 | 2023 | 15 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 1073 | 0.060 |
Why?
|
| Extremities | 1 | 2023 | 80 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2009 | 0.050 |
Why?
|
| Rituximab | 1 | 2024 | 157 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2002 | 56 | 0.050 |
Why?
|
| Tanzania | 1 | 2023 | 64 | 0.050 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2002 | 3 | 0.050 |
Why?
|
| DNA Footprinting | 1 | 2002 | 14 | 0.050 |
Why?
|
| Antibody Diversity | 1 | 2002 | 7 | 0.050 |
Why?
|
| Chimera | 1 | 2002 | 90 | 0.050 |
Why?
|
| Base Composition | 1 | 2002 | 72 | 0.050 |
Why?
|
| Mice, Inbred ICR | 1 | 2002 | 149 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2002 | 50 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2023 | 148 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 237 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2002 | 64 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2002 | 317 | 0.050 |
Why?
|
| Greece | 1 | 2022 | 10 | 0.050 |
Why?
|
| Head | 1 | 2022 | 101 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 147 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 204 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 172 | 0.050 |
Why?
|
| U937 Cells | 1 | 2001 | 26 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 160 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 715 | 0.050 |
Why?
|
| Exons | 3 | 2017 | 793 | 0.050 |
Why?
|
| Time Factors | 2 | 2008 | 6168 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 156 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2001 | 204 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 3886 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 459 | 0.050 |
Why?
|
| Giant Cells | 1 | 2000 | 35 | 0.050 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2020 | 9 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 240 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 52 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 92 | 0.040 |
Why?
|
| Pleurodesis | 1 | 2020 | 14 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 86 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2020 | 31 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2020 | 36 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 171 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 602 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 440 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 303 | 0.040 |
Why?
|
| STAT5 Transcription Factor | 1 | 2020 | 89 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 497 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2000 | 45 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 636 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 145 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2020 | 257 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2022 | 325 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2020 | 236 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 29 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 220 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2019 | 62 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1227 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2019 | 33 | 0.040 |
Why?
|
| Blood Cells | 1 | 2019 | 50 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 19 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2002 | 973 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2000 | 807 | 0.040 |
Why?
|
| Liver Failure | 1 | 2019 | 93 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 104 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 1008 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 99 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2000 | 679 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 81 | 0.040 |
Why?
|
| Stem Cells | 1 | 2002 | 710 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 658 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2019 | 392 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 578 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 330 | 0.040 |
Why?
|
| Software | 1 | 2002 | 669 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 143 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 149 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 184 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2018 | 139 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 374 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2017 | 50 | 0.040 |
Why?
|
| Foam Cells | 1 | 2017 | 20 | 0.040 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2017 | 33 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 138 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 54 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 27 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 99 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 300 | 0.040 |
Why?
|
| Etoposide | 1 | 2017 | 119 | 0.040 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 140 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 68 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 190 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 87 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2017 | 170 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 149 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 79 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 175 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1153 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 332 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 454 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1998 | 346 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 316 | 0.030 |
Why?
|
| Thrombosis | 1 | 2021 | 516 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 2700 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 269 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 317 | 0.030 |
Why?
|
| Prevalence | 1 | 2022 | 2322 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2001 | 1022 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 358 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 239 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 2019 | 443 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 206 | 0.030 |
Why?
|
| Streptonigrin | 1 | 1994 | 2 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1994 | 54 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 39 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 64 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2014 | 34 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6275 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2014 | 78 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 106 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 507 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2013 | 38 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 122 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2017 | 334 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2003 | 772 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 646 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1710 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 158 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 98 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 157 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1585 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 742 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1855 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 155 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 278 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 98 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 941 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 58 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 769 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2011 | 49 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 253 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2010 | 43 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1994 | 882 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1898 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 238 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1483 | 0.020 |
Why?
|
| Pedigree | 1 | 2013 | 1574 | 0.020 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 72 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 369 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2809 | 0.020 |
Why?
|
| Gene Library | 2 | 2001 | 220 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2001 | 260 | 0.020 |
Why?
|
| Introns | 2 | 2001 | 301 | 0.020 |
Why?
|
| Mortality | 1 | 2011 | 223 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2011 | 176 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2001 | 900 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 104 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3289 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 1189 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 551 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 558 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 805 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 7045 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 1164 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2003 | 53 | 0.010 |
Why?
|
| Cosmids | 1 | 2001 | 48 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2001 | 78 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 2001 | 85 | 0.010 |
Why?
|
| Poly A | 1 | 2001 | 59 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2001 | 139 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2001 | 212 | 0.010 |
Why?
|
| VDJ Recombinases | 1 | 2000 | 4 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 381 | 0.010 |
Why?
|
| TATA Box | 1 | 2000 | 25 | 0.010 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2000 | 42 | 0.010 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2000 | 18 | 0.010 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2000 | 22 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 129 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 465 | 0.010 |
Why?
|
| Dimerization | 1 | 2000 | 144 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 657 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2000 | 59 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 410 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 287 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2000 | 293 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 750 | 0.010 |
Why?
|
| Phylogeny | 1 | 2001 | 684 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 623 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2000 | 379 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 3601 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 1280 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 997 | 0.010 |
Why?
|